



S8 Fig. Progression-free survival of patients who underwent secondary cytoreductive surgery (CRS). (A) *BRCA* mutation group by the use of poly(ADP-ribose) polymerase inhibitor (PARPi) maintenance. (B) *BRCA* wild-type group by the use of bevacizumab maintenance. BEV, bevacizumab; CI, confidence interval.